Amneal Lifts 2026 Outlook on Strong Q2, Reprices Debt to Lower Interest Costs
AMRX has more than doubled off its 52-week low of $7.665.
Summary
Amneal posted Q2 2026 revenue of $796M (+10% YoY) and raised full-year guidance across revenue, adjusted EBITDA, and adjusted EPS. A debt repricing will lower interest costs by ~$12M annually, and an additional $350M term loan is planned to fund the Kashiv acquisition.
Key Events · Earnings and Guidance · AMRX
-
Q2 Revenue and Earnings Beat
Net revenue reached $796M, up 10% year-over-year, while GAAP net income more than doubled to $58M, or $0.18 diluted EPS. Adjusted EBITDA rose 12% to $206M, and adjusted diluted EPS came in at $0.30, compared with $0.25 a year ago.
-
Full-Year 2026 Guidance Raised
Revenue guidance was lifted to $3.10B–$3.20B (from $3.05B–$3.15B), adjusted EBITDA to $750M–$780M (from $740M–$770M), and adjusted diluted EPS to $0.96–$1.06 (from $0.95–$1.05). Capex was also increased to ~$150M, up from ~$110M.
-
Debt Repricing Cuts Interest Costs
The $2.084B Term Loan B was repriced to SOFR+250 bps from SOFR+300 bps, a 50-basis-point reduction expected to save ~$12M in annual cash interest. Closing could occur as early as August 3, 2026.
-
Additional $350M Term Loan for Kashiv Acquisition
To fund part of the Kashiv Biosciences acquisition, the company intends to obtain an additional $350M Term Loan B at the reduced pricing, with closing anticipated at deal completion.
Analysis · AMRX · Life Sciences
A 10% jump in net revenue to $796 million and a more than doubling of GAAP net income to $58 million powered a standout second quarter. Adjusted EBITDA climbed 12% to $206 million, while adjusted diluted EPS reached $0.30, comfortably ahead of the $0.25 recorded a year ago. With momentum building, management raised full-year 2026 guidance for the second time this year: revenue is now expected at $3.10–$3.20 billion, adjusted EBITDA at $750–$780 million, and adjusted diluted EPS at $0.96–$1.06. In a separate move to strengthen the balance sheet, the company repriced its $2.084 billion Term Loan B, trimming the rate by 50 basis points to SOFR plus 250, which should generate roughly $12 million in annual cash interest savings. An additional $350 million Term Loan B is planned to help fund the pending Kashiv Biosciences acquisition. Trading near its 52-week high, the stock reflects market confidence in the diversified portfolio and growth trajectory.
At the time of this filing, AMRX was trading at $21.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $7.67 to $19.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.